Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

Cancer Immunology, Immunotherapy

Volumn 52, Issue 9, 2003, Pages 576-582

  Colnot, David R ^a   Roos, Jan C ^a   De Bree, Remco ^a   Wilhelm, Abraham J ^a   Kummer, J Alain ^a   Hanft, Gertraud ^b   Heider, Karl Heinz ^c   Stehle, Gerd ^b   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

99mTc BIWA 4; CD44; Head and neck cancer; Humanized monoclonal antibodies; Radioimmunotherapy; Squamous cell carcinoma

Indexed keywords

BIVATUZUMAB; CD44V6 ANTIGEN; MONOCLONAL ANTIBODY TC 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COMPLEX FORMATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; TECHNETIUM;

EID: 0041854151     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0396-5     Document Type: Article

References (26)

1. Bosslet K, Steinstrasser A, Schwarz A, Harthus HP, Luben G, Kuhlmann L, Sedlacek HH (1988) Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 14:523-528
2. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA (1994) A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83:1760-1768
3. Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Borjesson PK, Huijgens PC, Snow GB, Van Dongen GAMS (2002) Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 8:3401-3406
4. Colnot DR, Quak JJ, Roos JC, Van Lingen A, Wilhelm AJ, Van Kamp GJ, Huijgens PC, Snow GB, Van Dongen GAMS (2000) Phase I therapy study of Rhenium-186-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41:1999-2010
5. De Bree R, Roos JC, Plaizier MA, Quak JJ, Van Kamp GJ, Den Hollander W, Snow GB, Van Dongen GAMS (1997) Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Brit J Cancer 75:1049-1060
6. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS (1995) Radioimmunoscintigraphy and biodistribution of 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1:591-598
7. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL (1997) Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 38:1180-1185
8. Heider K-H, Mulder J-WR, Ostermann E, Susani S, Patzelt E, Pals ST, Adolf GR (1995) Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 31A:2385-2391
9. Heider K-H, Sproll M, Susani S, Patzelt E, Beaumier PL, Ostermann E, Ahorn H, Adolf GR (1996) Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43:245-253
10. Himmler A, Maurer-Fogy I, Kronke M, Scheurich P, Pfizenmaier K, Lantz M, Olsson I, Hauptmann R, Stratowa C, Adolf GR (1990) Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol 9:705-715
11. Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, Shealy D, Doherty PW (1985) Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 26:849-858
12. Jung K, Lein MWS, Schnorr D, Henke W, Loening S (1996) Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Eur J Cancer 32A:627-630
13. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsch G, Wahl RL (2000) Radioimmunotherapy with iodine 131-I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266
14. Kittl EM, Ruckser R, Reich-Weichselbraun I, Hinterberger W, Bauer K (1997) Significant elevation of tumor-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Eur J Clin Chem Clin Biochem 35:81-84
15. Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H, Salako QA, Furmanski P, Glenn SD, DeNardo GL (1993) Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med 34:1067-1074
16. Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL (1998) Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 4:1679-1688
17. Kugelman LC, Ganguly S, Haggerty JG, Weissman SM, Milstone LM (1992) The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J Invest Dermatol 99:886-891
18. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
19. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942
20. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61:6851-6859
21. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ (1993) Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294-303
22. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, Van Dongen GAMS (2000) Safety and biodistribution of 99m-Technetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6:3046-3055
23. Van Gog FB, Visser GWM, Stroomer JWG, Roos JC, Snow GB, Van Dongen GAMS (1997) High dose rhenium-186 labeling of monoclonal antibodies for clinical application. Pitfalls and solutions. Cancer 80:2360-2370
24. Van Hal NLW, Van Dongen GAMS, Rood-Knippels EMC, Van der Valk P, Snow GB, Brakenhoff RH (1996) Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int J Cancer 68:520-527
25. Verel I, Heider K-H, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, Van Dongen GAMS (2002) Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 99:396-402
26. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Stgermain J, Richards EC, Larson SM, Old LJ (1996) Phase I/II study of 125-I labeled monoclonal antibody A33 in patients with advanced colorectal cancer. J Clin Oncol 14:1787-1797